---
canonical_name: P7C3
alternate_names: P7C3-A20, P7C3-S243
canonical_topic: P7C3 for Health & Longevity
short_topic_lc: p7c3
creation_date: 2026-1108-0859
creator_ai_fullname: Opus 5.5
ep_keywords: NAMPT Activators, Nicotinamide Phosphoribosyltransferase Activators, NAD+ Boosters, Aminopropyl Carbazoles
---

# P7C3 for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 11/08/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5

**Also known as:** P7C3-A20, P7C3-S243

  
## Motivation

<!-- This motivation section was written last, after every other section of this review was completed, so that it reflects the full scope of the topic rather than an early impression of it. -->

P7C3 is a laboratory-made molecule found in 2010 in a search that gave a thousand different chemicals to living mice and counted surviving newborn brain cells, and it was one of the handful the search singled out for closer study. It is thought to act by helping cells keep up their supply of a molecule that carries energy inside every cell, a supply that falls in aging tissue and during injury. That placed it at the centre of a question of interest to anyone thinking about a long healthspan: whether topping up cellular energy chemistry can slow or undo age-related decline.

Over the following fifteen years the compound and its chemical relatives were tested in a wide range of animals, including aged rats, mice bred to develop dementia-like changes, and a small group of monkeys. Most work centred on the brain, later on aging muscle. The compound is not sold as a medicine anywhere, and is supplied only for laboratory work.

This review examines what the published evidence shows and does not show about P7C3 in relation to health and lifespan, the quality of that evidence, the open questions about how it works, and what is known of its hazards.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

High-level overviews of P7C3 and of the cellular energy pathway it is thought to act on.

<!-- Search performed 2026-11-08. Web search was run for each priority platform paired with "P7C3" ("Rhonda Patrick P7C3", "Peter Attia P7C3", "Andrew Huberman P7C3", "Chris Kresser P7C3", "Life Extension P7C3", "lifespan.io P7C3"), and each platform's own search function was loaded through the Section 5 retrieval tiers. foundmyfitness.com: d-browser returned a Cloudflare bot wall, d-fetch returned HTTP 403, d-proxy-2 refused the host (no residential access), so no on-site result could be obtained. peterattiamd.com: d-proxy-2 refused the host; d-browser returned "Nothing Found" and "No results for P7C3". hubermanlab.com: d-browser returned only fuzzy matches (PEA, P5P, PCP) and no P7C3 content. chriskresser.com: d-browser returned "There are no search results for that term". lifeextension.com: d-browser returned the default product catalogue with no P7C3 match. lifespan.io: d-proxy-2 returned two relevant hits, of which the NAD+ decline feature is included below. General literature search was run through d-pubmed and web search for narrative reviews, editorials and expert commentary on P7C3. Systematic reviews and meta-analyses were excluded here and placed in the Systematic Reviews section. -->

* [Neuron-Protecting P7C3 Compounds Take Steps Toward the Clinic](https://www.alzforum.org/news/research-news/neuron-protecting-p7c3-compounds-take-steps-toward-clinic) - Amber Dance

  Specialist research commentary written when the enzyme target was first proposed, recounting the screen that found the compound, the crosslinking experiments behind the target claim, and the move of the programme into industry.

* [P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/24514864/) - Pieper et al., 2014

  Narrative review by the three discovering laboratories covering the screen, the chemistry campaign, and the animal models, with the pharmacology reported in full.

* [Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death](https://pubmed.ncbi.nlm.nih.gov/38580317/) - Velma et al., 2024

  Critical medicinal-chemistry review of compounds aimed at NAMPT (nicotinamide phosphoribosyltransferase, the enzyme that recycles the cell's energy carrier NAD⁺), the enzyme P7C3 is proposed to stimulate. It audits the binding data directly.

* [Small-molecule activation of NAMPT as a potential neuroprotective strategy](https://pubmed.ncbi.nlm.nih.gov/39872755/) - Gu et al., 2022

  Short perspective on the shared target of P7C3 and later compounds, NAMPT, explaining why stimulating this enzyme is thought to protect nerve cells.

* [Why NAD+ Declines During Aging – Part 1](https://lifespan.io/why-nad-declines-during-aging-part-1/) - Steve Hill

  Accessible account of the age-related fall in NAD⁺, the salvage pathway P7C3 is proposed to accelerate, and the human evidence for and against that decline.

No content discussing P7C3 was found on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com or lifeextension.com. The compound has never been available for human use, so consumer-facing health platforms have had little reason to cover it; the Lifespan.io item above was included because it covers the underlying pathway rather than the compound.

  
## Grokipedia

<!-- Search performed 2026-11-08. grokipedia.com was searched directly through d-browser (browser_navigate to the site's search URL for "P7C3", then browser_snapshot), which returned the site's results page listing 2 results: a dedicated "P7C3" article and a passing mention inside the "Nicotinamide phosphoribosyltransferase" article. No further tiers were needed. The dedicated article is linked below. -->

* [P7C3](https://grokipedia.com/page/p7c3)

  Covers the discovery screen, the chemical series, the proposed enzyme target and the animal models in one place, including the structure-activity data and the clinical development status.

  
## Examine

<!-- Search performed 2026-11-08. examine.com was searched directly through the Section 5 retrieval tiers in order: d-browser returned a Vercel Security Checkpoint interstitial with HTTP 429, d-fetch returned HTTP 429, and d-proxy-1 returned the site's own search results page reading "Sorry, there are no search results for P7C3." No further tier was needed. No Examine article exists. -->

No Examine article exists for P7C3. Examine.com covers supplements and nutrients sold for human use; P7C3 is a research chemical with no human formulation, which places it outside that scope.

  
## ConsumerLab

<!-- Search performed 2026-11-08. consumerlab.com was searched directly through the retrieval tiers in order: d-browser (browser_navigate to the site's search URL for "P7C3", then browser_snapshot) returned the site's own search results page reading "Sorry, we didn't find any results for P7C3", with the note that a search term may appear only in a members-only report. No further tiers were needed. No ConsumerLab article exists. -->

No ConsumerLab article exists for P7C3. ConsumerLab tests consumer supplement products for identity and purity; no P7C3 consumer product exists to test, which places it outside that scope.

  
## Systematic Reviews

Systematic reviews and meta-analyses covering P7C3.

<!-- Search performed 2026-11-08 with d-pubmed. Queries: "P7C3 AND (systematic review OR meta-analysis)" (1 result) and "(P7C3 OR \"aminopropyl carbazole\" OR \"P7C3-A20\")" filtered to the Systematic Review, Meta-Analysis and Scoping Review publication types (1 result, the same paper). Exactly one qualifying paper exists. -->

* [P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders](https://pubmed.ncbi.nlm.nih.gov/42698301/) - Chen et al., 2026

  The only systematic review of P7C3. Synthesises mechanism and preclinical efficacy, and names the safety and biomarker obstacles to clinical use.

Only one systematic review exists, and it addresses the claimed neuroprotective effect. No systematic review or meta-analysis addresses the principal risk of stimulating this enzyme — its established overexpression in malignancy — so the risk side of the trade-off is unrepresented in this section and is covered from primary sources in Potential Risks & Side Effects.

  
## Mechanism of Action

P7C3 is an aminopropyl carbazole, built on a flat three-ring core. It was not designed against a target; it emerged from a screen counting surviving newborn neurons in mouse hippocampus, the target proposed four years later.

The proposed mechanism is stimulation of NAMPT, the rate-limiting step in the salvage pathway that recycles nicotinamide into NAD⁺ (nicotinamide adenine dinucleotide, the carrier that shuttles energy and electrons inside cells). A modified derivative was found to bind NAMPT ([Wang 2014](https://pubmed.ncbi.nlm.nih.gov/25215490/)), and active variants enhanced purified NAMPT activity ([Wang 2014](https://pubmed.ncbi.nlm.nih.gov/25215490/)) — from the discovering laboratories, whose lead investigator co-founded Glengary Brain Health, Inc to commercialise it ([CWRU news release](https://case.edu/news/new-study-shows-how-protect-brain-prevent-depression-and-cognitive-impairment-caused-whole-brain-radiotherapy)). A systematic review proposes that restored NAD⁺ feeds the sirtuins SIRT1 and SIRT3 (enzymes that strip acetyl groups off proteins, tuning mitochondrial quality and oxidative stress) ([Chen 2026](https://pubmed.ncbi.nlm.nih.gov/42698301/)).

A medicinal-chemistry review records three laboratories independently failing to detect binding to, or activation of, recombinant human NAMPT by P7C3-A20 ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)); another finds no direct interaction between P7C3 and NAMPT by biophysical methods ([Tang 2023](https://pubmed.ncbi.nlm.nih.gov/36873168/)). Yet inhibiting NAMPT with FK866 blocked P7C3-A20's neuroprotection in rats, placing the enzyme in the causal chain ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)). A proteome screen found direct binding to phosphoglycerate kinase 1, a sugar-metabolism enzyme ([Chen 2021](https://pubmed.ncbi.nlm.nih.gov/34221965/)).

P7C3 was 32% orally bioavailable in mice ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)), with a plasma terminal half-life of 6.7 hours after intraperitoneal dosing ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). The analogue (-)-P7C3-S243 was reported nontoxic, orally bioavailable, metabolically stable and brain-penetrant ([Naidoo 2014](https://pubmed.ncbi.nlm.nih.gov/24697290/)). Selectivity, tissue distribution and human metabolising enzymes are unpublished.

  
## Historical Context & Evolution

P7C3 has no original intended use, because it was never designed for one. In 2010 a group computationally selected 1,000 drug-like compounds and infused them in pools of ten into the brain ventricles of living mice, then counted newborn neurons in the dentate gyrus. Eight increased neuron formation; P7C3 was the one with usable drug-like properties ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). That target-agnostic route is the historically unusual feature: efficacy came first, the molecular explanation later.

Interest in health optimisation followed from two findings in that first paper. Prolonged dosing of 18-month-old rats preserved water-maze performance and increased surviving new neurons, and the treated animals unexpectedly held body weight steady while controls lost weight with age ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). A compound acting on aging itself, rather than one disease, was the natural reading.

A chemistry campaign then produced more potent analogues ([Naidoo 2014](https://pubmed.ncbi.nlm.nih.gov/24697290/)). The 2014 identification of NAMPT as the binding partner ([Wang 2014](https://pubmed.ncbi.nlm.nih.gov/25215490/)) moved the compound into the NAD⁺ field, then expanding around nicotinamide riboside and nicotinamide mononucleotide.

The mechanistic account did not settle. A medicinal-chemistry review records that independent groups could not reproduce direct NAMPT binding ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)), and the discovering laboratories shifted to the more cautious language of restoring NAD⁺ homeostasis rather than raising NAD⁺ ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). What changed, on both sides, is the evidence about the target, not the animal efficacy data, which have been reproduced across laboratories and species. Sixteen years after discovery the compound remains preclinical, with no registered human study.

  
## Expected Benefits

<!-- Search performed 2026-11-08 using d-pubmed and web search. Queries covered "P7C3[tiab] OR P7C3-A20[tiab] OR P7C3-S243[tiab]" (92 records, all screened by title), plus targeted queries pairing P7C3 with aging, muscle, bone, diabetes, cognition, depression, stroke and primate. Searches deliberately included designs reporting no effect or the opposite effect: this surfaced Hill 2018 (no protection against Wallerian degeneration, plus concentration-dependent neurotoxicity), the Velma 2024 audit of the diabetes NAD+ data, and the three independent failures to detect NAMPT binding. ClinicalTrials.gov was searched through d-clinicaltrialsgov (intervention query "P7C3"; free-text "aminopropyl carbazole OR NAMPT activator"): zero records. No human outcome data of any design were found, which is why every item below is graded Speculative. -->

Every benefit below rests on animal or cell data. For a healthspan-focused audience these are hypotheses about human physiology, not effects obtainable today.

### High 🟩 🟩 🟩

No benefit reaches High: High requires a human clinical endpoint or validated clinical surrogate replicated across independent research groups, and no study of P7C3 in humans of any design has been published.

### Medium 🟩 🟩

No benefit reaches Medium: Medium requires that same class of human outcome in at least a single trial or in controlled observational data, and no human data on P7C3 exist.

### Low 🟩

No benefit reaches Low: Low requires uncontrolled or indirect human data such as case series or case reports, and there is not a single published human exposure to P7C3.

### Speculative 🟨

#### Preservation of Learning and Memory in Normal Aging

Daily P7C3 in 18-month-old rats preserved water-maze performance and tripled surviving new hippocampal neurons over two months ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). No human cognitive outcome data exist.

#### Survival of Newborn Hippocampal Neurons ⚠️ Conflicted

A rhesus macaque pilot showed more surviving new neurons ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)); neuron cultures showed no protection and dose-dependent loss of nerve-cell projections ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)). Net reading: the signal appears in whole animals, not isolated neurons.

#### Reversal of Alzheimer's-Type Neurodegeneration in Mice

P7C3-A20 given from 6 to 12 months of age reversed tau phosphorylation, barrier damage and cognitive loss in two mouse models ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). Entirely animal; no patient data.

#### Protection of Dopamine-Producing Neurons

Aminopropyl carbazoles blocked neurotoxin-induced loss of substantia nigra dopamine neurons in mice and worms ([De Jesús-Cortés 2012](https://pubmed.ncbi.nlm.nih.gov/23027934/)). A separate group reproduced protection, measuring senescence (cells that stop dividing yet persist) ([Chen 2024](https://pubmed.ncbi.nlm.nih.gov/39056208/)).

#### Skeletal Muscle Function in Old Age

Four weeks of P7C3 in two-year-old mice improved muscle contractility, shifted fibres towards larger sizes and preserved grip strength ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)). Described by its authors as preliminary; single laboratory.

#### Bone Mass Preservation

P7C3 reduced bone loss in ovariectomised rats modelling post-menopausal osteoporosis ([Wei 2024](https://pubmed.ncbi.nlm.nih.gov/38477537/)) and in aged mice with senile osteoporosis ([Bai 2025](https://pubmed.ncbi.nlm.nih.gov/39543818/)). No human bone data.

#### Glucose Control and Insulin Sensitivity

Four weeks of P7C3 in diabetic db/db mice lowered fasting blood glucose and raised insulin secretion ([Manickam 2022](https://pubmed.ncbi.nlm.nih.gov/35060352/)). A medicinal-chemistry review calls the accompanying muscle NAD⁺ figures problematic ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)).

#### Relief of Depressive-Like Behaviour

P7C3 compounds reduced depressive-like behaviour in stressed mice, an effect eliminated when hippocampal stem cells were ablated by radiation ([Walker 2015](https://pubmed.ncbi.nlm.nih.gov/24751964/)). Rodent behaviour only; no human mood data.

#### Protection of Nerves After Acute Injury

A review records that P7C3 compounds preserved function after brain injury across laboratories ([Sridharan 2023](https://pubmed.ncbi.nlm.nih.gov/37651054/)), and they protected rodents after spinal cord injury ([Duan 2019](https://pubmed.ncbi.nlm.nih.gov/31718264/)) and stroke ([Wang 2016](https://pubmed.ncbi.nlm.nih.gov/27333812/)). Never tested in an injured person.

  
## Benefit-Modifying Factors

No human study of P7C3 exists, so no factor below has been shown to modify a benefit in a person. Each is a mechanistic expectation drawn from the preclinical work and labelled as such.

* **Baseline energy-carrier depletion:** P7C3-A20 is characterised as restoring NAD⁺ balance under stress rather than raising it above normal, and did not elevate brain NAD⁺/NADH above normal in healthy mice ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). Benefit would then depend on prior depletion.

* **Genetic polymorphisms:** No pharmacogenetic data exist. The compound's proposed target enzyme is NAMPT; a medicinal-chemistry review reports that NAMPT heterozygous mice lost the glucose-lowering response to P7C3-A20 ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)), implying target-gene dose may matter, but no human variant has been studied.

* **Age:** The clearest cognitive signal came in 18-month-old rats rather than young animals ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)), and the muscle signal came in two-year-old mice ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)). Effects in young, healthy tissue are largely untested.

* **Pre-existing health conditions:** Benefit in animals required a disease or injury insult — diabetes, brain injury, amyloid pathology, ovariectomy. No animal study has shown a functional gain in an uninjured, young, healthy animal.

* **Sex-based differences:** The Alzheimer's reversal work reported no sex-specific differences in drug exposure or NAD⁺ response in mice ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). The muscle and primate studies used male animals only, so female data are thin.

  
## Potential Risks & Side Effects

<!-- Search performed 2026-11-08. No prescribing information, DailyMed label, drugs.com monograph or Mayo Clinic entry exists for P7C3, because it has never been approved or marketed for human use; the absence was confirmed by web search and by the Examine and ConsumerLab searches above. Side-effect evidence was therefore sought from primary literature via d-pubmed, pairing P7C3 with toxicity, safety, neurotoxicity, cancer, tumour, immune and pharmacokinetics, and from the two reviews that audit the compound critically (Velma 2024, Tang 2023). The search deliberately covered designs reporting no excess risk: the 38-week rhesus macaque study found no microscopic toxicology in any of 35 tissues examined, and Naidoo 2014 reported the S243 analogue nontoxic — both are reflected in the items below. -->

No human exposure to P7C3 has been documented, so no adverse event has ever been observed in a person. For a healthspan-focused audience the governing hazard is the absence of human safety data itself.

### High 🟥 🟥 🟥

No risk reaches High: High requires documented human adverse events or a validated clinical surrogate replicated across independent research groups, and no human exposure to P7C3 has been published.

### Medium 🟥 🟥

No risk reaches Medium: Medium requires that class of human outcome in a single trial or in controlled observational data, and no human data on P7C3 exist.

### Low 🟥

No risk reaches Low: Low requires uncontrolled human data such as case reports or case series, and no case report of P7C3 exposure in a person has been published.

### Speculative 🟨

#### Degeneration of Nerve-Cell Projections at Higher Exposures

In mouse ganglion and cortical neuron cultures, P7C3-A20 caused concentration-dependent degeneration of nerve-cell projections at 500 nM and above ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)). The highest non-toxic concentration at 24 hours was 100 nM ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)).

#### Stimulating an Enzyme Overexpressed in Malignancy

NAMPT, the enzyme P7C3 is proposed to stimulate, is elevated in several human cancers and tied to higher tumour stage and worse prognosis, a review reports ([Shackelford 2013](https://pubmed.ncbi.nlm.nih.gov/24386506/)). No tumour-incidence study of P7C3 exists.

#### Off-Target Inhibition of a Glycolytic Enzyme

A human proteome screen found P7C3 binds phosphoglycerate kinase 1 directly and reduced its activity, suppressing aerobic glycolysis (sugar burning for energy) in glioma cells ([Chen 2021](https://pubmed.ncbi.nlm.nih.gov/34221965/)). Consequences in healthy tissue are untested.

#### Suppression of Th17 Immune Responses

P7C3 attenuated central nervous system autoimmunity in mice by inhibiting differentiation of Th17 cells (an inflammation-driving subset of immune T cells) ([Li 2021](https://pubmed.ncbi.nlm.nih.gov/32647376/)). Whether this raises infection risk is unstudied.

#### Cell Death at High Concentrations

In renal cell carcinoma cultures, P7C3 at concentrations above those used for neuroprotection killed cells outright, with 60 µM causing 43.89% cell death ([Shu 2024](https://pubmed.ncbi.nlm.nih.gov/38356717/)). Selectivity for tumour over normal cells is unresolved.

#### Central Depressant Effects Through GABA Signalling

P7C3 injected into the spinal fluid produced pain relief in rats through GABA (gamma-aminobutyric acid, the brain's principal calming messenger) ([Ryu 2021](https://pubmed.ncbi.nlm.nih.gov/33727053/)). Whether systemic dosing causes sedation in people is unstudied.

  
## Risk-Modifying Factors

No human exposure to P7C3 has been published, so no factor below has been shown to modify risk in a person. Each is inferred from the preclinical pharmacology.

* **Pre-existing or occult malignancy:** A review reports the proposed target enzyme overexpressed in several cancers and tied to worse prognosis ([Shackelford 2013](https://pubmed.ncbi.nlm.nih.gov/24386506/)). The systematic review calls stimulating it in someone with an undetected tumour the most frequently named hazard of this drug class ([Chen 2026](https://pubmed.ncbi.nlm.nih.gov/42698301/)).

* **Exposure level:** Toxicity in cell culture was concentration-dependent, appearing at 500 nM and above ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)), while 100 nM was non-toxic ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)). With no human pharmacokinetic data, no exposure in a person can be mapped onto that threshold.

* **Genetic polymorphisms:** No pharmacogenetic data exist for P7C3. The human enzymes that metabolise it have not been published, so variants in drug-metabolising genes cannot be assessed, and neither can variants in the proposed target gene.

* **Baseline biomarker levels:** No biomarker has been validated as predicting harm. The single systematic review names the absence of validated predictive biomarkers as one of three obstacles to clinical use ([Chen 2026](https://pubmed.ncbi.nlm.nih.gov/42698301/)).

* **Sex-based differences:** The 38-week primate safety study used only male rhesus macaques ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)), and the aged-muscle study only male mice ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)). Female-specific hazards are therefore largely unexamined.

* **Age and organ reserve:** Rodent and primate safety work used healthy adult animals with intact liver and kidney function. No animal study has dosed animals with impaired clearance, so age-related decline in elimination is an untested variable.

  
## Key Interactions & Contraindications

<!-- Search performed 2026-11-08 with d-pubmed: "P7C3 AND (\"drug interaction\" OR pharmacokinetics OR CYP OR metabolism OR \"plasma protein binding\")" (66 records screened) and "(NAMPT activator OR SBI-797812) AND (P7C3 OR neuroprotective)" (57 records). No human interaction study and no human pharmacokinetic study of P7C3 exists. The pairings found are all in animals or cells: FK866 (NAMPT inhibitor), nicotinamide, paclitaxel, doxorubicin. Because 20.11 requires a product label, a regulator, or a human study, every pairing below sits under the theoretical label. -->

**Documented interactions:**

* None identified. No human interaction or pharmacokinetic study of P7C3 has been published, and no product label or regulatory assessment exists, so no interaction meets the documented standard.

**Theoretical interactions (inferred from mechanism, not studied in humans):**

* **NAMPT inhibitors (FK866, KPT-9274, daporinad):** Inferred from opposing action on the same enzyme. FK866 completely abolished P7C3-A20's protective effect in rats ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)); loss of effect, not toxicity, is the expected consequence. No human pairing exists.

* **Nicotinamide and other NAD⁺ precursors (nicotinamide riboside, nicotinamide mononucleotide):** Inferred from shared substrate supply to the salvage pathway. Nicotinamide raised a subthreshold dose of P7C3-A20 to full efficacy in rats ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)); additive effect expected, magnitude unknown in people.

* **Taxane chemotherapy (paclitaxel, docetaxel):** Inferred from converging effects on nerve energy supply. P7C3-A20 blocked paclitaxel-induced allodynia (pain from a touch that should not hurt) in tumoured mice without reducing antitumour efficacy ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)). Whether that separation holds in people is untested.

* **Anthracyclines (chemotherapy drugs such as doxorubicin and daunorubicin):** Inferred from NAD⁺ depletion by anthracyclines. Active P7C3 compounds reversed doxorubicin-induced NAD⁺ loss and its toxicity in cells ([Wang 2014](https://pubmed.ncbi.nlm.nih.gov/25215490/)). Interference with intended cytotoxicity cannot be excluded.

* **Central nervous system depressants (benzodiazepines, alcohol, and gabapentinoids — nerve-pain medicines such as gabapentin and pregabalin):** Inferred from GABA-mediated pain relief after P7C3 was injected into the spinal fluid of rats ([Ryu 2021](https://pubmed.ncbi.nlm.nih.gov/33727053/)). Additive sedation is the mechanistic expectation; no pharmacodynamic study has tested it.

* **CYP3A4 (a liver enzyme that breaks down many drugs) inhibitors and inducers (ketoconazole, ritonavir, grapefruit juice, rifampicin, carbamazepine):** Inferred from the compound's fat-soluble structure and liver clearance in rodents. Its human metabolising enzymes are unidentified, so the size of any exposure change is unknown.

* **Over-the-counter sedating medicines (diphenhydramine, doxylamine, promethazine):** Inferred from the same GABA-mediated central effect as the prescription depressants above; additive drowsiness is the expectation. No over-the-counter medicine has been tested with P7C3 in any species.

* **Over-the-counter niacin and nicotinamide products:** Inferred from shared substrate supply to the salvage pathway, the same mechanism as the prescription-free precursors above. The size of any additive effect in people is unknown.

**Populations who should avoid P7C3:**

* **Anyone outside a regulated research protocol:** Inferred from the absence of any human safety, dose-ranging or toxicology study, and from the compound's supply status as laboratory reagent rather than medicine; no human data of any kind exist.

* **People with active or previously treated malignancy:** Inferred from a review reporting NAMPT overexpression in several cancers and its association with higher tumour stage and worse prognosis ([Shackelford 2013](https://pubmed.ncbi.nlm.nih.gov/24386506/)); no human data on P7C3 in cancer.

* **People receiving cytotoxic chemotherapy:** Inferred from P7C3's reversal of doxorubicin-induced NAD⁺ depletion and cytotoxicity in cells ([Wang 2014](https://pubmed.ncbi.nlm.nih.gov/25215490/)), which raises the possibility of blunting intended tumour cell killing; no human data.

* **Pregnancy and lactation:** Inferred from the absence of any reproductive or developmental toxicology study for P7C3, together with its demonstrated passage into brain tissue in rodents ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)); no human data.

* **People with an autoimmune condition on immunosuppressive therapy:** Inferred from suppression of Th17 differentiation in mice ([Li 2021](https://pubmed.ncbi.nlm.nih.gov/32647376/)), which raises a theoretical additive immunosuppression concern; no human data.

  
## Risk Mitigation Strategies

Because no human protocol exists, no mitigation strategy below has been validated in a person. Parameters without a citation reflect common practice in preclinical pharmacology rather than clinical experience.

* **Restriction to a regulated protocol:** The single systematic review names on-target safety, missing biomarkers and prior NAMPT trial failures as unresolved obstacles ([Chen 2026](https://pubmed.ncbi.nlm.nih.gov/42698301/)). Formal Phase 1 dose-escalation is the only setting in which human exposure is characterised.

* **Baseline malignancy screening:** Addresses the risk of stimulating an enzyme a review reports overexpressed in cancer ([Shackelford 2013](https://pubmed.ncbi.nlm.nih.gov/24386506/)). Age-appropriate cancer screening before any exposure, and a documented absence of active malignancy, is the mitigation a research protocol would apply.

* **Exposure ceiling below the in-vitro toxic threshold:** Addresses degeneration of nerve-cell projections, which appeared at 500 nM ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)) and was absent at 100 nM in neuron cultures ([Hill 2018](https://pubmed.ncbi.nlm.nih.gov/30334859/)). Without human pharmacokinetic data no amount maps to that ceiling.

* **Avoidance of concurrent NAD⁺ precursors:** Addresses unquantified additive effect, since nicotinamide raised a subthreshold P7C3-A20 dose to full efficacy in rats ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)). Separating the two prevents an unmeasurable combined exposure.

* **Identity and purity verification of any material:** Addresses the risk of an unintended compound entirely, since research-grade supply carries no pharmacopoeial identity standard. Certificate of analysis with mass spectrometry and nuclear magnetic resonance data is the laboratory norm.

* **Liver and kidney function checks:** Address undetected organ toxicity, which the 38-week primate study did not find microscopically but which no human study has excluded ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)). Liver enzymes and filtration rate are the standard panel.

  
## Therapeutic Protocol

No therapeutic protocol for P7C3 exists. The compound has never been given to a person in a published study, no clinic or practitioner has a regimen for it, and no dose has been established as safe or effective in humans. What follows describes the regimens used in animals, which is the only dosing evidence that exists. Parameters without a citation reflect common practice in preclinical pharmacology.

* **Animal dose, parent compound:** Peak new-neuron formation in adult mice occurred at oral doses of 5 mg/kg and above, with graded loss of effect at 2.5 and 1 mg/kg ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). Aged rats received 10 mg/kg daily ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)).

* **Animal dose, P7C3-A20 analogue:** Mouse studies of Alzheimer's-type pathology used 10 mg/kg/day by intraperitoneal injection ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). The rhesus macaque study used 10 mg/kg/day orally for 38 weeks ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)).

* **Competing approaches:** Sources differ on which agent is the validated tool for this target: P7C3-A20 has the animal efficacy record, while SBI-797812 is the compound shown to bind and activate the enzyme directly ([Tang 2023](https://pubmed.ncbi.nlm.nih.gov/36873168/)).

* **No human dose conversion:** Animal milligram-per-kilogram figures do not convert to human doses without body-size scaling (allometric scaling) and human drug-handling data, neither of which has been published for P7C3. No human-equivalent dose can be stated.

* **Half-life:** Plasma terminal half-life was 6.7 hours after intraperitoneal dosing in mice ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)), with a brain-to-plasma exposure ratio of 3.7 ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)). Human half-life is unmeasured.

* **Single versus split dosing:** Every published animal regimen used once-daily dosing. In macaques, once-daily oral dosing gave peak levels around 4 hours ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)) and a trough of 73–132 ng/ml at 24 hours ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)).

* **Best time of day:** No study has compared dosing times. Animal protocols dosed once daily without reporting time of day as a variable, and no circadian interaction with the target pathway has been tested for this compound.

* **Genetic polymorphisms:** No pharmacogenetic data exist. A medicinal-chemistry review reports that NAMPT heterozygous mice lost the glucose-lowering response ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)), suggesting target-gene dose could matter, but no human variant has been studied.

* **Sex-based differences:** Drug exposure and NAD⁺ response showed no sex difference in mice ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). The primate and aged-muscle studies used males only, so sex as a dosing variable is effectively unexamined.

* **Age-related considerations:** Animal efficacy was concentrated in old animals — 18-month rats ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)) and two-year-old mice ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)). No study has adjusted dose for age-related decline in clearance, in any species.

* **Baseline biomarker levels:** The compound is described as restoring energy-carrier balance under stress rather than raising it above normal ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)). No baseline measurement has been validated as predicting response.

* **Pre-existing health conditions:** Animal benefit required an insult — diabetes, injury, amyloid pathology or ovariectomy. No regimen has been studied in animals with organ impairment, and none in animals bearing tumours apart from the paclitaxel model.

  
## Discontinuation & Cycling

* **Intended duration:** Undefined for humans. Animal regimens ranged from 7 days of dosing to the longest mammalian exposure, 38 weeks in macaques ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)). No study has addressed lifelong versus short-term use.

* **Persistence after stopping:** In mice treated for 30 days one year after brain injury, the recovery persisted for months after treatment stopped ([Vázquez-Rosa 2020](https://pubmed.ncbi.nlm.nih.gov/33087571/)). Whether durability extends further, or to other outcomes, is untested.

* **Withdrawal effects:** None reported. No animal study has described a rebound, withdrawal syndrome or loss-of-effect phenomenon after stopping, and with no human exposure no withdrawal effect could have been observed.

* **Tapering:** Not applicable to any published protocol. All animal studies stopped dosing abruptly at the end of the treatment window without reported consequence, and no tapering schedule has been proposed or tested.

* **Cycling:** Untested. No animal study has compared continuous with intermittent dosing, so whether cycling would preserve or reduce effect is unknown. The argument for it rests on limiting cumulative exposure to a compound without chronic human safety data.

  
## Sourcing and Quality

* **Regulatory supply status:** P7C3 is not an approved medicine in any jurisdiction and has no pharmaceutical formulation. It is supplied by chemical catalogue houses as a laboratory reagent, labelled for research use only and not for diagnostic or therapeutic purposes.

* **No pharmacopoeial standard:** Because no regulator has assessed the compound, no official monograph defines its identity, purity limits, impurity profile or permissible residual solvents. Research-grade material is sold against a vendor's own specification, not an external standard.

* **What a certificate of analysis documents:** Laboratory practice looks for stated purity by high-performance liquid chromatography, structural confirmation by nuclear magnetic resonance and mass spectrometry, batch number, and residual solvent data. Vendor certificates vary in which of these they include.

* **Distinguishing the analogues:** Three distinct molecules share the name stem — P7C3, P7C3-A20 and (-)-P7C3-S243 — and they differ in potency and in whether the material is a single mirror-image form (enantiomer) ([Naidoo 2014](https://pubmed.ncbi.nlm.nih.gov/24697290/)). Catalogue listings do not always make the distinction clear.

* **Formulation:** No oral human formulation exists. Animal work used dimethyl sulfoxide with Cremophor, or an oil-and-syrup vehicle for primate oral dosing ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)); the compound's poor water solubility is the reason.

* **Compounding pharmacies:** No compounding pharmacy prepares P7C3. US compounding law restricts bulk ingredients to those meeting a pharmacopoeial monograph, forming part of an approved drug product, or appearing on the FDA's 503A bulks list ([FDA 503A bulks guidance](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act)); P7C3 meets none.

  
## Practical Considerations

* **Regulatory status:** Not approved as a medicine in any jurisdiction, and not a dietary supplement ingredient. It has no off-label status either, because off-label use presupposes an approved product. Supply is as a research chemical only.

* **Time to effect:** Unknown in humans. In animals, new neuron formation rose within 7 days of dosing ([Pieper 2010](https://pubmed.ncbi.nlm.nih.gov/20603013/)), while cognitive and pathological reversal required 1 to 6 months of continuous treatment ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)).

* **Common pitfalls:** Reading a mouse milligram-per-kilogram dose as a human dose; treating the three named analogues as interchangeable; and reading the "reversal of Alzheimer's" result ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)), obtained in mice, as a demonstration in people.

* **Mechanism uncertainty as a practical matter:** A medicinal-chemistry review records three laboratories failing to detect binding to the proposed target enzyme ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)). An unresolved mechanism means off-target effects cannot be anticipated or monitored for.

* **Cost and accessibility:** Research-grade material is sold in milligram quantities at research-reagent prices, which are high per gram but not prohibitive for the quantities catalogues list. Accessibility is limited by supply status rather than by cost.

* **Development status:** The compound is being advanced by Glengary Brain Health, Inc, co-founded by the lead investigator of the discovering laboratory to develop and commercialise the technology ([CWRU news release](https://case.edu/news/new-study-shows-how-protect-brain-prevent-depression-and-cognitive-impairment-caused-whole-brain-radiotherapy)).

  
## Interaction with Foundational Habits

* **Sleep:** No direct interaction has been studied. An indirect, mechanistically plausible link exists: the target pathway is regulated by the circadian clock, and a separate study showed the clock protein Period3 raises the activity of the same enzyme in mice ([Xie 2025](https://pubmed.ncbi.nlm.nih.gov/39894345/)). No sleep outcome has been measured with P7C3.

* **Nutrition:** Potentiating. Nicotinamide, the substrate of the target enzyme and a form of vitamin B3 present in food and supplements, raised a subthreshold dose of P7C3-A20 to full efficacy in rats ([LoCoco 2017](https://pubmed.ncbi.nlm.nih.gov/29125463/)). Dietary niacin intake would therefore be an uncontrolled variable.

* **Exercise:** No direct interaction has been studied. In two-year-old mice, P7C3 improved muscle contractility and preserved grip strength but left muscle fatigue unchanged ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)), so an additive effect on strength adaptations is plausible and an endurance effect is not. No study combined the two.

* **Stress management:** Indirect. In mice, chronic social defeat stress reduced survival of new hippocampal neurons, and P7C3 given during that stress preserved them and reduced depressive-like behaviour ([Walker 2015](https://pubmed.ncbi.nlm.nih.gov/24751964/)). The animal effect was conditional on the stressor being present; no cortisol measurement was reported.

  
## Monitoring Protocol & Defining Success

No human monitoring protocol for P7C3 exists, and no biomarker has been validated as tracking either its benefit or its harm. The table below lists only the safety checks that the preclinical toxicology and mechanism point to, together with the one biomarker that an animal study has linked to the compound's effect. Comprehensive tissue pathology after 38 weeks of oral dosing in macaques found no microscopic toxicity in any of the organs examined ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)), which is the only systematic safety screen that exists in a primate. Ongoing monitoring in a research setting would follow the cadence that Phase 1 work uses for a first-in-human small molecule: baseline, then at 2 and 4 weeks, then every 4–12 weeks while exposure continues. No frequency has been established for this compound, and none of these intervals rests on a P7C3 study.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Alanine aminotransferase (ALT) | 7–56 U/L (standard reference range) | Safety check: liver injury from an unapproved small molecule with unidentified human metabolism | ALT is a liver enzyme released when liver cells are damaged. No sourced optimal functional range exists for this compound. Non-fasting. Paired with aspartate aminotransferase and bilirubin |
| Estimated glomerular filtration rate (eGFR) | ≥90 mL/min/1.73 m² (standard reference range) | Safety check: kidney clearance is uncharacterised in humans, and kidney cell toxicity appeared at high concentrations in culture ([Shu 2024](https://pubmed.ncbi.nlm.nih.gov/38356717/)) | eGFR is a calculated measure of how fast the kidneys filter blood. No sourced optimal functional range exists. Calculated from creatinine; affected by muscle mass and recent protein intake |
| Complete blood count with differential | Standard laboratory reference ranges by age and sex (standard reference range) | Safety check: the compound suppressed Th17 cell differentiation in mice ([Li 2021](https://pubmed.ncbi.nlm.nih.gov/32647376/)), and bone marrow is a tissue the primate study examined ([Bauman 2018](https://pubmed.ncbi.nlm.nih.gov/30258178/)) | No sourced optimal functional range exists. Lymphocyte subsets are not captured by a routine differential |
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Expected to change: P7C3 lowered fasting glucose and raised insulin secretion in diabetic mice ([Manickam 2022](https://pubmed.ncbi.nlm.nih.gov/35060352/)) | No sourced optimal functional range exists for this compound. Requires 8-hour fast. Paired with glycated haemoglobin for a longer-term view |
| Plasma phosphorylated tau 217 (p-tau217) | No established target; track change from the individual's own baseline | Expected to change: P7C3-A20 reduced plasma p-tau217 in mice ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)), the only biomarker an animal study has linked to its effect | p-tau217 is a blood marker of Alzheimer's-type brain change. Assay availability and cut-points differ between laboratories; change from baseline is what the animal study measured |

Qualitative markers that an animal-to-human translation would track:

* Subjective cognitive clarity and recall, since the animal cognitive signal was in hippocampus-dependent learning
* Mood and anhedonia (loss of pleasure in things normally enjoyed), since the animal behavioural signal was in depressive-like behaviour
* Daytime sedation, given the GABA-mediated effect seen after dosing into the spinal fluid in rats
* Grip and functional strength, the outcome the aged-mouse muscle study measured
* Any new or unexplained symptom, which in a compound with no human exposure record carries more weight than any of the above

  
## Emerging Research

* **No registered human trial:** ClinicalTrials.gov returned zero records for P7C3, P7C3-A20 and for the free-text terms "aminopropyl carbazole" and "NAMPT activator" (searched 2026-11-08, no NCT ID exists). The compound has no trial to report results from, and none to anticipate results from.

* **First-in-human safety work:** Development sits with Glengary Brain Health, Inc, co-founded by the discovering laboratory's lead investigator ([CWRU news release](https://case.edu/news/new-study-shows-how-protect-brain-prevent-depression-and-cognitive-impairment-caused-whole-brain-radiotherapy)). A clean first safety study would move every item here from Speculative towards testable; a safety failure would end the programme.

* **Alzheimer's reversal in mice:** The 2026 report that advanced disease was reversed in two mouse models, with normalisation of 46 proteins also altered in human Alzheimer's brain ([Chaubey 2026](https://pubmed.ncbi.nlm.nih.gov/41435831/)), is the strongest preclinical claim made for the compound and the direct rationale for moving it toward a first human study.

* **Durability of the reversal:** The reported mouse benefit persisted for months after dosing stopped in the brain injury model ([Vázquez-Rosa 2020](https://pubmed.ncbi.nlm.nih.gov/33087571/)). Whether reversal of amyloid-driven pathology is permanent is stated as an open question, and follow-up work is testing it.

* **The target controversy:** Whether P7C3 acts on NAMPT at all remains open, with a medicinal-chemistry review recording three laboratories unable to detect binding ([Velma 2024](https://pubmed.ncbi.nlm.nih.gov/38580317/)) and later chemistry reporting that the best-validated direct activators are urea-type compounds related to known NAMPT inhibitors ([Tang 2023](https://pubmed.ncbi.nlm.nih.gov/36873168/)). Resolution either way would reshape the animal data.

* **Research that could weaken the case:** A review of NAMPT in malignancy ([Shackelford 2013](https://pubmed.ncbi.nlm.nih.gov/24386506/)) and the cancer-cell findings at higher P7C3 concentrations ([Shu 2024](https://pubmed.ncbi.nlm.nih.gov/38356717/)) make carcinogenicity testing the study most capable of ending the programme. No such study has been published.

* **Aging-specific outcomes:** The first aged-animal muscle study appeared only in 2026 and is described by its authors as preliminary ([Manickam 2026](https://pubmed.ncbi.nlm.nih.gov/42764081/)). No lifespan or mortality study in any species has been published, which is a notable gap for a compound discussed in longevity terms.

  
## Conclusion

P7C3 is a laboratory molecule, not a treatment. It was found by accident of design — a screen looking for anything that protected newborn brain cells in living mice — and has since protected nerve cells, muscle and bone across many animal models, including a small monkey study. The most striking claim is that advanced dementia-like damage in mice was not merely slowed but undone.

None of this has been tested in a person. Sixteen years on there is no human study of any size or design, no registered trial, no approved product and no established dose. That gap is the central fact of this review, and it caps every benefit and risk listed here at the weakest level of evidence, however consistent the animal work looks.

Two further uncertainties matter. How the compound works is disputed: several independent laboratories could not detect it acting on the enzyme it is said to act on, leaving its effects on other targets unpredictable. And that enzyme is more active in several cancers, a concern no study of this compound has addressed. A conflict of interest also runs through the evidence, much of which comes from the laboratory that found the molecule and whose lead researcher co-founded the company developing it. The strongest safety finding — nearly nine months of daily dosing in monkeys with no visible tissue damage — cannot stand in for human data. The animal evidence is interesting; it is also, for now, all there is.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**


